{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:16:11Z","timestamp":1792808171216,"version":"4.5.0"},"reference-count":213,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In autoimmune rheumatic diseases (ARDs), T\u00a0cells mistakenly attack the body\u2019s own joints, skin, blood vessels, and other tissues, leading to chronic inflammation and tissue damage. Among these, the immune balance between T helper 17 lymphocytes (Th17) and regulatory T lymphocytes (Treg) is a foundation for maintaining normal immune function in the human body. An immune imbalance between Th17 and Treg cells is one of the key pathogenic mechanisms in ARDs. The percentages of Th17 and Treg cells can serve as important indicators for the severity of autoimmune diseases and treatment response. Therefore, by studying the origin and function of Th17 and Treg cells as well as the cytokine microenvironment that regulates their differentiation, we aim to modulate the immune state by restoring cellular balance. This approach is particularly relevant in ARDs such as rheumatoid arthritis, Sj\u00f6gren\u2019s syndrome, systemic lupus erythematosus, scleroderma, and ankylosing spondylitis. It also summarizes the current clinical application of disease-modifying anti-rheumatic drugs in regulating the balance between Th17 and Treg cells, with the aim of providing guidance for clinical practice.<\/jats:p>","DOI":"10.1515\/biol-2025-1285","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:03:57Z","timestamp":1772730237000},"source":"Crossref","is-referenced-by-count":6,"title":["The Th17\/Treg axis: a key to understanding and treating autoimmune disorders"],"prefix":"10.1515","volume":"21","author":[{"given":"Xiangrui","family":"Xie","sequence":"first","affiliation":[{"name":"College of Acupuncture and Massage, Changchun University of Chinese Medicine , Changchun , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"College of Acupuncture and Massage, Changchun University of Chinese Medicine , Changchun , China"},{"name":"Acupuncture Department , Affiliated Hospital of Changchun University of Chinese Medicine , Changchun , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijing","family":"Li","sequence":"additional","affiliation":[{"name":"College of Acupuncture and Massage, Changchun University of Chinese Medicine , Changchun , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2026030517035207501_j_biol-2025-1285_ref_001","doi-asserted-by":"crossref","unstructured":"Gray, KJ, Gibbs, JE. Adaptive immunity, chronic inflammation and the clock. Semin Immunopathol 2022;44:209\u201324. https:\/\/doi.org\/10.1007\/s00281-022-00919-7.","DOI":"10.1007\/s00281-022-00919-7"},{"key":"2026030517035207501_j_biol-2025-1285_ref_002","doi-asserted-by":"crossref","unstructured":"Groen, SS, Bay-Jensen, AC, Thudium, CS, Dziegiel, MH, Skougaard, M, Thomsen, SF, et al.. Evaluating the inhibition of IL-17A and TNF\u03b1 in a cartilage explant model cultured with Th17-derived cytokines. J\u00a0Transl Autoimmun 2024;8:100231. https:\/\/doi.org\/10.1016\/j.jtauto.2024.100231.","DOI":"10.1016\/j.jtauto.2024.100231"},{"key":"2026030517035207501_j_biol-2025-1285_ref_003","doi-asserted-by":"crossref","unstructured":"Fang, K, Zong, J, Chang, X. Progress and future perspectives of treg cell therapy. Front Biosci (Landmark Ed) 2025;30:41250. https:\/\/doi.org\/10.31083\/fbl41250.","DOI":"10.31083\/FBL41250"},{"key":"2026030517035207501_j_biol-2025-1285_ref_004","doi-asserted-by":"crossref","unstructured":"Thomas, R, Qiao, S, Yang, X. Th17\/Treg imbalance: implications in lung inflammatory diseases. Int J Mol Sci 2023;24:4865. https:\/\/doi.org\/10.3390\/ijms24054865.","DOI":"10.3390\/ijms24054865"},{"key":"2026030517035207501_j_biol-2025-1285_ref_005","doi-asserted-by":"crossref","unstructured":"Li, G, Xiong, Y, Li, Z, Yu, Q, Li, S, Xie, J, et al.. Gut microbiota-derived metabolites modulate Treg\/Th17 balance: novel therapeutic targets in autoimmune diseases. Front Immunol 2025;16:1710733. https:\/\/doi.org\/10.3389\/fimmu.2025.1710733.","DOI":"10.3389\/fimmu.2025.1710733"},{"key":"2026030517035207501_j_biol-2025-1285_ref_006","doi-asserted-by":"crossref","unstructured":"Wang, Z, Xu, Z, Zong, M, Fan, L. Metabolic regulation of Th17 and Treg cell balance by the mTOR signaling. Metabol Open 2025;26:100369. https:\/\/doi.org\/10.1016\/j.metop.2025.100369.","DOI":"10.1016\/j.metop.2025.100369"},{"key":"2026030517035207501_j_biol-2025-1285_ref_007","doi-asserted-by":"crossref","unstructured":"Chen, Y, Zhang, XS, Wang, YG, Lu, C, Li, J, Zhang, P. Imbalance of Th17 and Tregs in thymoma may be a pathological mechanism of myasthenia gravis. Mol Immunol 2021;133:67\u201376. https:\/\/doi.org\/10.1016\/j.molimm.2021.02.011.","DOI":"10.1016\/j.molimm.2021.02.011"},{"key":"2026030517035207501_j_biol-2025-1285_ref_008","doi-asserted-by":"crossref","unstructured":"Wang, Y, Li, N, Li, Q, Liu, Z, Li, Y, Kong, J, et al.. Xuanbai chengqi decoction ameliorates pulmonary inflammation via reshaping gut microbiota and rectifying Th17\/Treg imbalance in a murine model of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2021;16:3317\u201335. https:\/\/doi.org\/10.2147\/copd.s337181.","DOI":"10.2147\/COPD.S337181"},{"key":"2026030517035207501_j_biol-2025-1285_ref_009","doi-asserted-by":"crossref","unstructured":"Qiu, P, Ishimoto, T, Fu, L, Zhang, J, Zhang, Z, Liu, Y. The gut microbiota in inflammatory bowel disease. Front Cell Infect Microbiol 2022;12:733992. https:\/\/doi.org\/10.3389\/fcimb.2022.733992.","DOI":"10.3389\/fcimb.2022.733992"},{"key":"2026030517035207501_j_biol-2025-1285_ref_010","doi-asserted-by":"crossref","unstructured":"Thye, AYK, Bah, YR, Law, JWF, Tan, LTH, He, YW, Wong, SH, et al.. Gut-skin axis: unravelling the connection between the gut microbiome and psoriasis. Biomedicines 2022;10:1037. https:\/\/doi.org\/10.3390\/biomedicines10051037.","DOI":"10.3390\/biomedicines10051037"},{"key":"2026030517035207501_j_biol-2025-1285_ref_011","doi-asserted-by":"crossref","unstructured":"Teng, F, Klinger, CN, Felix, KM, Pierce Bradley, C, Wu, E, Tran, NL, et al.. Gut microbiota drive autoimmune arthritis by promoting differentiation and migration of peyer\u2019s patch T follicular helper cells. Immunity 2016;44:875\u201388. https:\/\/doi.org\/10.1016\/j.immuni.2016.03.013.","DOI":"10.1016\/j.immuni.2016.03.013"},{"key":"2026030517035207501_j_biol-2025-1285_ref_012","doi-asserted-by":"crossref","unstructured":"Olejniczak-Staruch, I, Ci\u0105\u017cy\u0144ska, M, Sobolewska-Sztychny, D, Narbutt, J, Skibinska, M, Lesiak, A. Alterations of the skin and gut microbiome in psoriasis and psoriatic arthritis. Int J Mol Sci 2021;22:3998. https:\/\/doi.org\/10.3390\/ijms22083998.","DOI":"10.3390\/ijms22083998"},{"key":"2026030517035207501_j_biol-2025-1285_ref_013","doi-asserted-by":"crossref","unstructured":"Yang, J, Su, J, Chai, K, Liu, H. The role of Th9 CD4+ T\u00a0cells and IL-9 during primary Sjogren\u2019s syndrome. J\u00a0Clin Lab Anal 2022;36:e24646. https:\/\/doi.org\/10.1002\/jcla.24646.","DOI":"10.1002\/jcla.24646"},{"key":"2026030517035207501_j_biol-2025-1285_ref_014","doi-asserted-by":"crossref","unstructured":"Zhu, E, Wang, X, Zheng, B, Wang, Q, Hao, J, Chen, S, et al.. miR-20b suppresses Th17 differentiation and the pathogenesis of experimental autoimmune encephalomyelitis by targeting ROR\u03b3t and STAT3. J\u00a0Immunol 2014;192:5599\u2013609. https:\/\/doi.org\/10.4049\/jimmunol.1303488.","DOI":"10.4049\/jimmunol.1303488"},{"key":"2026030517035207501_j_biol-2025-1285_ref_015","doi-asserted-by":"crossref","unstructured":"Yang, P, Qian, FY, Zhang, MF, Xu, AL, Wang, X, Jiang, BP, et al.. Th17 cell pathogenicity and plasticity in rheumatoid arthritis. J\u00a0Leukoc Biol 2019;106:1233\u201340. https:\/\/doi.org\/10.1002\/jlb.4ru0619-197r.","DOI":"10.1002\/JLB.4RU0619-197R"},{"key":"2026030517035207501_j_biol-2025-1285_ref_016","doi-asserted-by":"crossref","unstructured":"Nakagawa, H, Koyama, R, Kamada, Y, Ochida, A, Kono, M, Shirai, J, et al.. Biochemical properties of TAK-828F, a potent and selective retinoid-related orphan receptor gamma t inverse agonist. Pharmacology 2018;102:244\u201352. https:\/\/doi.org\/10.1159\/000492226.","DOI":"10.1159\/000492226"},{"key":"2026030517035207501_j_biol-2025-1285_ref_017","doi-asserted-by":"crossref","unstructured":"Du, Y, Fang, Q, Zheng, SG. Regulatory T\u00a0cells: concept, classification, phenotype, and biological characteristics. Adv Exp Med Biol 2021;1278:1\u201331.","DOI":"10.1007\/978-981-15-6407-9_1"},{"key":"2026030517035207501_j_biol-2025-1285_ref_018","doi-asserted-by":"crossref","unstructured":"Shen, J, Yang, L, You, K, Chen, T, Su, Z, Cui, Z, et al.. Indole-3-Acetic acid alters intestinal microbiota and alleviates ankylosing spondylitis in mice. Front Immunol 2022;13:762580. https:\/\/doi.org\/10.3389\/fimmu.2022.762580.","DOI":"10.3389\/fimmu.2022.762580"},{"key":"2026030517035207501_j_biol-2025-1285_ref_019","doi-asserted-by":"crossref","unstructured":"Zhang, W, Liu, X, Zhu, Y, Liu, X, Gu, Y, Dai, Y, et al.. Transcriptional and posttranslational regulation of Th17\/Treg balance in health and disease. Eur J Immunol 2021;51:2137\u201350. https:\/\/doi.org\/10.1002\/eji.202048794.","DOI":"10.1002\/eji.202048794"},{"key":"2026030517035207501_j_biol-2025-1285_ref_020","doi-asserted-by":"crossref","unstructured":"Guo, X, Jiang, C, Chen, Z, Wang, X, Hong, F, Hao, D. Regulation of the JAK\/STAT signaling pathway in spinal cord injury: an updated review. Front Immunol 2023;14:1276445. https:\/\/doi.org\/10.3389\/fimmu.2023.1276445.","DOI":"10.3389\/fimmu.2023.1276445"},{"key":"2026030517035207501_j_biol-2025-1285_ref_021","doi-asserted-by":"crossref","unstructured":"Goetsch, A, D\u2019Amico, F, Allocca, M, Fiorino, G, Furfaro, F, Zilli, A, et al.. Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors. Expert Opin Pharmacother 2023;24:849\u201361. https:\/\/doi.org\/10.1080\/14656566.2023.2200931.","DOI":"10.1080\/14656566.2023.2200931"},{"key":"2026030517035207501_j_biol-2025-1285_ref_022","doi-asserted-by":"crossref","unstructured":"Luo, Y, Alexander, M, Gadina, M, OShea, JJ, Meylan, F, Schwartz, DM. JAK-STAT signaling in human disease: from genetic syndromes to clinical inhibition. J\u00a0Allergy Clin Immunol 2021;148:911\u201325. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.004.","DOI":"10.1016\/j.jaci.2021.08.004"},{"key":"2026030517035207501_j_biol-2025-1285_ref_023","doi-asserted-by":"crossref","unstructured":"Hu, Q, Bian, Q, Rong, D, Wang, L, Song, J, Huang, H-S, et al.. JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens. Front Bioeng Biotechnol 2023;11:1110765. https:\/\/doi.org\/10.3389\/fbioe.2023.1110765.","DOI":"10.3389\/fbioe.2023.1110765"},{"key":"2026030517035207501_j_biol-2025-1285_ref_024","doi-asserted-by":"crossref","unstructured":"Hu, X, Li, J, Fu, M, Zhao, X, Wang, W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Targeted Ther 2021;6:402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1.","DOI":"10.1038\/s41392-021-00791-1"},{"key":"2026030517035207501_j_biol-2025-1285_ref_025","doi-asserted-by":"crossref","unstructured":"Glassman, CR, Tsutsumi, N, Saxton, RA, Lupardus, PJ, Jude, KM, Garcia, KC. Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science 2022;376:163\u20139. https:\/\/doi.org\/10.1126\/science.abn8933.","DOI":"10.1126\/science.abn8933"},{"key":"2026030517035207501_j_biol-2025-1285_ref_026","doi-asserted-by":"crossref","unstructured":"Wan, Z, Zhou, Z, Liu, Y, Lai, Y, Luo, Y, Peng, X, et al.. Regulatory T\u00a0cells and T helper 17 cells in viral infection. Scand J Immunol 2020;91:e12873. https:\/\/doi.org\/10.1111\/sji.12873.","DOI":"10.1111\/sji.12873"},{"key":"2026030517035207501_j_biol-2025-1285_ref_027","unstructured":"Dong, L, Zheng, X, Wang, G. Peritoneal adhesions induce Th17\/Treg imbalance in mice. Int J Clin Exp Pathol 2018;11:4352\u201362."},{"key":"2026030517035207501_j_biol-2025-1285_ref_028","doi-asserted-by":"crossref","unstructured":"Heinrich, PC, Behrmann, I, M\u00fcller-Newen, G, Schaper, F, Graeve, L. Interleukin-6-type cytokine signalling through the gp130\/Jak\/STAT pathway. Biochem J 1998;334:297\u2013314. https:\/\/doi.org\/10.1042\/bj3340297.","DOI":"10.1042\/bj3340297"},{"key":"2026030517035207501_j_biol-2025-1285_ref_029","doi-asserted-by":"crossref","unstructured":"Fasching, P, Stradner, M, Graninger, W, Dejaco, C, Fessler, J. Therapeutic potential of targeting the Th17\/Treg axis in autoimmune disorders. Molecules 2017;22:134. https:\/\/doi.org\/10.3390\/molecules22010134.","DOI":"10.3390\/molecules22010134"},{"key":"2026030517035207501_j_biol-2025-1285_ref_030","doi-asserted-by":"crossref","unstructured":"Wcis\u0142o-Dziadecka, D, Zbiciak-Nylec, M, Brzezi\u0144ska-Wcis\u0142o, L, Bebenek, K, Ka\u017amierczak, A. Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors. Dermatol Ther 2017;30:e12555. https:\/\/doi.org\/10.1111\/dth.12555.","DOI":"10.1111\/dth.12555"},{"key":"2026030517035207501_j_biol-2025-1285_ref_031","doi-asserted-by":"crossref","unstructured":"Peter, AE, Sandeep, BV, Rao, BG, Kalpana, VL. Calming the storm: natural immunosuppressants as adjuvants to target the cytokine storm in COVID-19. Front Pharmacol 2021;11:583777. https:\/\/doi.org\/10.3389\/fphar.2020.583777.","DOI":"10.3389\/fphar.2020.583777"},{"key":"2026030517035207501_j_biol-2025-1285_ref_032","doi-asserted-by":"crossref","unstructured":"Mohammad, TAM, Hamad, BK, Maroof, AMA, Mahmud, SO. STA-21 regulates Th-17\/Treg balance and synovial fibroblasts functions in rheumatoid arthritis. Int J Rheum Dis 2024;27:e15032. https:\/\/doi.org\/10.1111\/1756-185x.15032.","DOI":"10.1111\/1756-185X.15032"},{"key":"2026030517035207501_j_biol-2025-1285_ref_033","doi-asserted-by":"crossref","unstructured":"Liang, D, Wang, Q, Zhang, W, Tang, H, Song, C, Yan, Z, et al.. JAK\/STAT in leukemia: a clinical update. Mol Cancer 2024;23:25. https:\/\/doi.org\/10.1186\/s12943-023-01929-1.","DOI":"10.1186\/s12943-023-01929-1"},{"key":"2026030517035207501_j_biol-2025-1285_ref_034","doi-asserted-by":"crossref","unstructured":"Xie, D, Zhu, S, Bai, L. Lactic acid in tumor microenvironments causes dysfunction of NKT\u00a0cells by interfering with mTOR signaling. Sci China Life Sci 2016;59:1290\u20136. https:\/\/doi.org\/10.1007\/s11427-016-0348-7.","DOI":"10.1007\/s11427-016-0348-7"},{"key":"2026030517035207501_j_biol-2025-1285_ref_035","doi-asserted-by":"crossref","unstructured":"Du, Z, Wang, J, Liu, Q, Yang, D, Sun, X, Huang, L, et al.. SHIP-1 regulates the differentiation and function of Tregs via inhibiting mTORC1 activity. Cell Mol Life Sci 2024;82:10. https:\/\/doi.org\/10.1007\/s00018-024-05470-2.","DOI":"10.1007\/s00018-024-05470-2"},{"key":"2026030517035207501_j_biol-2025-1285_ref_036","doi-asserted-by":"crossref","unstructured":"Szredzka, A, Chwastowicz, A, Pergo\u0142, J, Matryba, P. Circadian clocks and adaptive immune function: from mechanisms to therapeutic applications. Front Immunol 2025;16:1697854. https:\/\/doi.org\/10.3389\/fimmu.2025.1697854.","DOI":"10.3389\/fimmu.2025.1697854"},{"key":"2026030517035207501_j_biol-2025-1285_ref_037","doi-asserted-by":"crossref","unstructured":"Saviano, A, Manosour, AA, Raucci, F, Merlino, F, Marigliano, N, Schettino, A, et al.. New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A\/F function. Ann Rheum Dis 2023;82:1415\u201328. https:\/\/doi.org\/10.1136\/ard-2023-224479.","DOI":"10.1136\/ard-2023-224479"},{"key":"2026030517035207501_j_biol-2025-1285_ref_038","doi-asserted-by":"crossref","unstructured":"Nagai, S, Kurebayashi, Y, Koyasu, S. Role of PI3K\/Akt and mTOR complexes in Th17 cell differentiation. Ann N Y Acad Sci 2013;1280:30\u20134. https:\/\/doi.org\/10.1111\/nyas.12059.","DOI":"10.1111\/nyas.12059"},{"key":"2026030517035207501_j_biol-2025-1285_ref_039","doi-asserted-by":"crossref","unstructured":"Ren, W, Yin, J, Duan, J, Liu, G, Tan, B, Yang, G, et al.. mTORC1 signaling and IL-17 expression: defining pathways and possible therapeutic targets. Eur J Immunol 2016;46:291\u20139. https:\/\/doi.org\/10.1002\/eji.201545886.","DOI":"10.1002\/eji.201545886"},{"key":"2026030517035207501_j_biol-2025-1285_ref_040","doi-asserted-by":"crossref","unstructured":"Lawrence, J, Nho, R. The role of the mammalian target of rapamycin (mTOR) in pulmonary fibrosis. Int J Mol Sci 2018;19:778. https:\/\/doi.org\/10.3390\/ijms19030778.","DOI":"10.3390\/ijms19030778"},{"key":"2026030517035207501_j_biol-2025-1285_ref_041","doi-asserted-by":"crossref","unstructured":"Xin, X, Chen, X, Zeng, F, Xu, Q, Hou, L. The role of TGF-\u03b2\/SMAD signaling in hepatocellular carcinoma: from mechanism to therapy and prognosis. Int J Biol Sci 2024;20.","DOI":"10.7150\/ijbs.89568"},{"key":"2026030517035207501_j_biol-2025-1285_ref_042","doi-asserted-by":"crossref","unstructured":"Hu, HH, Chen, DQ, Wang, YN, Feng, YL, Cao, G, Vaziri, ND, et al.. New insights into TGF-\u03b2\/Smad signaling in tissue fibrosis. Chem Biol Interact 2018;292:76\u201383. https:\/\/doi.org\/10.1016\/j.cbi.2018.07.008.","DOI":"10.1016\/j.cbi.2018.07.008"},{"key":"2026030517035207501_j_biol-2025-1285_ref_043","doi-asserted-by":"crossref","unstructured":"Yang, I, Son, Y, Shin, JH, Kim, IY, Seong, JK. Ahnak depletion accelerates liver regeneration by modulating the TGF-\u03b2\/Smad signaling pathway. BMB Rep 2022;55:401\u20136. https:\/\/doi.org\/10.5483\/bmbrep.2022.55.8.071.","DOI":"10.5483\/BMBRep.2022.55.8.071"},{"key":"2026030517035207501_j_biol-2025-1285_ref_044","doi-asserted-by":"crossref","unstructured":"Hata, A, Chen, YG. TGF-\u03b2 signaling from receptors to smads. Cold Spring Harb Perspect Biol 2016;8:a022061. https:\/\/doi.org\/10.1101\/cshperspect.a022061.","DOI":"10.1101\/cshperspect.a022061"},{"key":"2026030517035207501_j_biol-2025-1285_ref_045","doi-asserted-by":"crossref","unstructured":"Zhan, Q, Zhang, J, Lin, Y, Chen, W, Fan, X, Zhang, D. Pathogenesis and treatment of Sjogren\u2019s syndrome: review and update. Front Immunol 2023;14:1127417. https:\/\/doi.org\/10.3389\/fimmu.2023.1127417.","DOI":"10.3389\/fimmu.2023.1127417"},{"key":"2026030517035207501_j_biol-2025-1285_ref_046","doi-asserted-by":"crossref","unstructured":"Khan, H, Yadav, N, Sharma, S, Rawat, R. Management of rheumatoid arthritis by development of nanocarriers and their significance over conventional dosage forms. Recent Adv Drug Deliv Formul 2025;19:2\u201315. https:\/\/doi.org\/10.2174\/0126673878324613240805065651.","DOI":"10.2174\/0126673878324613240805065651"},{"key":"2026030517035207501_j_biol-2025-1285_ref_047","doi-asserted-by":"crossref","unstructured":"Zeng, HQ, Yuan, ZDF, Wu, RT, Huang, ZH. Research progress on complications of rheumatoid arthritis. Front Immunol 2025;16:1561926. https:\/\/doi.org\/10.3389\/fimmu.2025.1561926.","DOI":"10.3389\/fimmu.2025.1561926"},{"key":"2026030517035207501_j_biol-2025-1285_ref_048","doi-asserted-by":"crossref","unstructured":"Van der Woude, D, Van der Helm-van Mil, AHM. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2018;32:174\u201387. https:\/\/doi.org\/10.1016\/j.berh.2018.10.005.","DOI":"10.1016\/j.berh.2018.10.005"},{"key":"2026030517035207501_j_biol-2025-1285_ref_049","doi-asserted-by":"crossref","unstructured":"Wang, X, Sun, B, Wang, Y, Gao, P, Song, J, Chang, W, et al.. Research progress of targeted therapy regulating Th17\/Treg balance in bone immune diseases. Front Immunol 2024;15:1333993. https:\/\/doi.org\/10.3389\/fimmu.2024.1333993.","DOI":"10.3389\/fimmu.2024.1333993"},{"key":"2026030517035207501_j_biol-2025-1285_ref_050","doi-asserted-by":"crossref","unstructured":"Jiang, Q, Yang, G, Liu, Q, Wang, S, Cui, D. Function and role of regulatory T\u00a0cells in rheumatoid arthritis. Front Immunol 2021;12:626193. https:\/\/doi.org\/10.3389\/fimmu.2021.626193.","DOI":"10.3389\/fimmu.2021.626193"},{"key":"2026030517035207501_j_biol-2025-1285_ref_051","doi-asserted-by":"crossref","unstructured":"Wagner, A, Wang, C, Fessler, J, DeTomaso, D, Avila-Pacheco, J, Kaminski, J, et al.. Metabolic modeling of single Th17 cells reveals regulators of autoimmunity. Cell 2021;184:4168\u201385.e21. https:\/\/doi.org\/10.1016\/j.cell.2021.05.045.","DOI":"10.1016\/j.cell.2021.05.045"},{"key":"2026030517035207501_j_biol-2025-1285_ref_052","doi-asserted-by":"crossref","unstructured":"Yan, S, Kotschenreuther, K, Deng, S, Kofler, DM. Regulatory T\u00a0cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential. Cell Mol Life Sci 2022;79:533. https:\/\/doi.org\/10.1007\/s00018-022-04563-0.","DOI":"10.1007\/s00018-022-04563-0"},{"key":"2026030517035207501_j_biol-2025-1285_ref_053","doi-asserted-by":"crossref","unstructured":"Ju, JH, Heo, YJ, Cho, ML, Jhun, JY, Park, JS, Lee, SY, et al.. Modulation of STAT-3 in rheumatoid synovial T\u00a0cells suppresses Th17 differentiation and increases the proportion of Treg cells. Arthritis Rheum 2012;64:3543\u201352. https:\/\/doi.org\/10.1002\/art.34601.","DOI":"10.1002\/art.34601"},{"key":"2026030517035207501_j_biol-2025-1285_ref_054","doi-asserted-by":"crossref","unstructured":"Paradowska-Gorycka, A, Wajda, A, Romanowska-Pr\u00f3chnicka, K, Walczuk, E, Kuca-Warnawin, E, Kmiolek, T, et al.. Th17\/Treg-Related transcriptional factor expression and cytokine profile in patients with rheumatoid arthritis. Front Immunol 2020;11:572858. https:\/\/doi.org\/10.3389\/fimmu.2020.572858.","DOI":"10.3389\/fimmu.2020.572858"},{"key":"2026030517035207501_j_biol-2025-1285_ref_055","doi-asserted-by":"crossref","unstructured":"Gautam, S, Kumar, R, Kumar, U, Kumar, S, Luthra, K, Dada, R. Yoga maintains Th17\/Treg cell homeostasis and reduces the rate of T\u00a0cell aging in rheumatoid arthritis: a randomized controlled trial. Sci Rep 2023;13:14924. https:\/\/doi.org\/10.1038\/s41598-023-42231-w.","DOI":"10.1038\/s41598-023-42231-w"},{"key":"2026030517035207501_j_biol-2025-1285_ref_056","doi-asserted-by":"crossref","unstructured":"Wang, T, Rui, J, Shan, W, Xue, F, Feng, D, Dong, L, et al.. Imbalance of Th17, Treg, and helper innate lymphoid cell in the peripheral blood of patients with rheumatoid arthritis. Clin Rheumatol 2022;41:3837\u201349. https:\/\/doi.org\/10.1007\/s10067-022-06315-8.","DOI":"10.1007\/s10067-022-06315-8"},{"key":"2026030517035207501_j_biol-2025-1285_ref_057","doi-asserted-by":"crossref","unstructured":"Kmio\u0142ek, T, Rzeszotarska, E, Wajda, A, Walczuk, E, Kuca-Warnawin, E, Romanowska-Pr\u00f3chnicka, K, et al.. The interplay between transcriptional factors and MicroRNAs as an important factor for Th17\/Treg balance in RA patients. Int J Mol Sci 2020;21:7169. https:\/\/doi.org\/10.3390\/ijms21197169.","DOI":"10.3390\/ijms21197169"},{"key":"2026030517035207501_j_biol-2025-1285_ref_058","doi-asserted-by":"crossref","unstructured":"Wang, W, Shao, S, Jiao, Z, Guo, M, Xu, H, Wang, S. The Th17\/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol Int 2012;32:887\u201393. https:\/\/doi.org\/10.1007\/s00296-010-1710-0.","DOI":"10.1007\/s00296-010-1710-0"},{"key":"2026030517035207501_j_biol-2025-1285_ref_059","doi-asserted-by":"crossref","unstructured":"Han, L, Yan, J, Li, T, Shen, P, Ba, X, Lin, W, et al.. Wutou decoction alleviates arthritis inflammation in CIA mice by regulating Treg cell stability and Treg\/Th17 balance via the JAK2\/STAT3 pathway. J\u00a0Ethnopharmacol 2024;334:118463. https:\/\/doi.org\/10.1016\/j.jep.2024.118463.","DOI":"10.1016\/j.jep.2024.118463"},{"key":"2026030517035207501_j_biol-2025-1285_ref_060","doi-asserted-by":"crossref","unstructured":"Feng, W, Wan, X, Fan, S, Liu, C-Z, Zheng, X-X, Liu, Q-P, et al.. Mechanism underlying the action of Duanteng-Yimu Tang in regulating Treg\/Th17 imbalance and anti-rheumatoid arthritis. Heliyon 2023;9:e15867. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15867.","DOI":"10.1016\/j.heliyon.2023.e15867"},{"key":"2026030517035207501_j_biol-2025-1285_ref_061","doi-asserted-by":"crossref","unstructured":"Zhong, H, Liu, S, Wang, Y, Xu, D, Li, M, Zhao, Y, et al.. Primary Sj\u00f6gren\u2019s syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis. Autoimmun Rev 2022;21:103084. https:\/\/doi.org\/10.1016\/j.autrev.2022.103084.","DOI":"10.1016\/j.autrev.2022.103084"},{"key":"2026030517035207501_j_biol-2025-1285_ref_062","doi-asserted-by":"crossref","unstructured":"Negrini, S, Emmi, G, Greco, M, Borro, M, Sardanelli, F, Murdaca, G, et al.. Sj\u00f6gren\u2019s syndrome: a systemic autoimmune disease. Clin Exp Med 2022;22:9\u201325. https:\/\/doi.org\/10.1007\/s10238-021-00728-6.","DOI":"10.1007\/s10238-021-00728-6"},{"key":"2026030517035207501_j_biol-2025-1285_ref_063","doi-asserted-by":"crossref","unstructured":"Beydon, M, McCoy, S, Nguyen, Y, Sumida, T, Mariette, X, Seror, R. Epidemiology of sj\u00f6gren syndrome. Nat Rev Rheumatol 2024;20:158\u201369. https:\/\/doi.org\/10.1038\/s41584-023-01057-6.","DOI":"10.1038\/s41584-023-01057-6"},{"key":"2026030517035207501_j_biol-2025-1285_ref_064","doi-asserted-by":"crossref","unstructured":"Dias, LH, Miyamoto, ST, Giovelli, RA, de Magalh\u00e3es, CIM, Valim, V. Pain and fatigue are predictors of quality of life in primary Sj\u00f6gren\u2019s syndrome. Adv Rheumatol 2021;61:28. https:\/\/doi.org\/10.1186\/s42358-021-00181-9.","DOI":"10.1186\/s42358-021-00181-9"},{"key":"2026030517035207501_j_biol-2025-1285_ref_065","doi-asserted-by":"crossref","unstructured":"Xin, X, Wang, Q, Qing, J, Song, W, Gui, Y, Li, X, et al.. Th17 cells in primary Sj\u00f6gren\u2019s syndrome negatively correlate with increased Roseburia and Coprococcus. Front Immunol 2022;13:974648. https:\/\/doi.org\/10.3389\/fimmu.2022.974648.","DOI":"10.3389\/fimmu.2022.974648"},{"key":"2026030517035207501_j_biol-2025-1285_ref_066","doi-asserted-by":"crossref","unstructured":"Wang, J, She, C, Li, Z, Tang, N, Xu, L, Liu, Z, et al.. In vitro impact of bisphenol A on maturation and function of monocyte-derived dendritic cells in patients with primary Sj\u00f6gren\u2019s syndrome. Immunopharmacol Immunotoxicol 2020;42:28\u201336. https:\/\/doi.org\/10.1080\/08923973.2019.1706554.","DOI":"10.1080\/08923973.2019.1706554"},{"key":"2026030517035207501_j_biol-2025-1285_ref_067","doi-asserted-by":"crossref","unstructured":"Ma, D, Wu, Z, Zhao, X, Zhu, X, An, Q, Wang, Y, et al.. Immunomodulatory effects of umbilical mesenchymal stem cell-derived exosomes on CD4+ T\u00a0cells in patients with primary Sj\u00f6gren\u2019s syndrome. Inflammopharmacology 2023;31:1823\u201338. https:\/\/doi.org\/10.1007\/s10787-023-01189-x.","DOI":"10.1007\/s10787-023-01189-x"},{"key":"2026030517035207501_j_biol-2025-1285_ref_068","doi-asserted-by":"crossref","unstructured":"Feng, M, Meng, F, Wang, Y, Jia, Y, Ji, G, Jin, Y, et al.. Assessment of the potential impact of polymorphisms in the Foxp3 and CTLA-4 genes in immune balance and disease susceptibility of primary Sj\u00f6gren\u2019s syndrome. Pharmacogenet Genomics 2025;35:159\u201369. https:\/\/doi.org\/10.1097\/fpc.0000000000000567.","DOI":"10.1097\/FPC.0000000000000567"},{"key":"2026030517035207501_j_biol-2025-1285_ref_069","doi-asserted-by":"crossref","unstructured":"Luo, J, Ming, B, Zhang, C, Deng, X, Li, P, Wei, Z, et al.. IL-2 inhibition of Th17 generation rather than induction of treg cells is impaired in primary Sj\u00f6gren\u2019s syndrome patients. Front Immunol 2018;9:1755. https:\/\/doi.org\/10.3389\/fimmu.2018.01755.","DOI":"10.3389\/fimmu.2018.01755"},{"key":"2026030517035207501_j_biol-2025-1285_ref_070","doi-asserted-by":"crossref","unstructured":"Li, B, Xing, Y, Gan, Y, He, J, Hua, H. Labial gland-derived mesenchymal stem cells and their exosomes ameliorate murine Sj\u00f6gren\u2019s syndrome by modulating the balance of Treg and Th17 cells. Stem Cell Res Ther 2021;12:478. https:\/\/doi.org\/10.1186\/s13287-021-02541-0.","DOI":"10.1186\/s13287-021-02541-0"},{"key":"2026030517035207501_j_biol-2025-1285_ref_071","doi-asserted-by":"crossref","unstructured":"Zheng, X, Wang, Q, Yuan, X, Zhou, Y, Chu, H, Wang, G, et al.. B7-H4 inhibits the development of primary Sj\u00f6gren\u2019s syndrome by regulating treg differentiation in NOD\/Ltj mice. J\u00a0Immunol Res 2020;2020:4896727. https:\/\/doi.org\/10.1155\/2020\/4896727.","DOI":"10.1155\/2020\/4896727"},{"key":"2026030517035207501_j_biol-2025-1285_ref_072","doi-asserted-by":"crossref","unstructured":"Zucchi, D, Elefante, E, Schilir\u00f2, D, Signorini, V, Trentin, F, Bortoluzzi, A, et al.. One year in review 2022: systemic lupus erythematosus. Clin Exp Rheumatol 2022;40:4\u201314. https:\/\/doi.org\/10.55563\/clinexprheumatol\/nolysy.","DOI":"10.55563\/clinexprheumatol\/nolysy"},{"key":"2026030517035207501_j_biol-2025-1285_ref_073","doi-asserted-by":"crossref","unstructured":"Tian, J, Zhang, D, Yao, X, Huang, Y, Lu, Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis 2023;82:351\u20136. https:\/\/doi.org\/10.1136\/ard-2022-223035.","DOI":"10.1136\/ard-2022-223035"},{"key":"2026030517035207501_j_biol-2025-1285_ref_074","doi-asserted-by":"crossref","unstructured":"Kiriakidou, M, Ching, CL. Systemic lupus erythematosus. Ann Intern Med 2020;172:ITC81\u201396. https:\/\/doi.org\/10.7326\/aitc202006020.","DOI":"10.7326\/AITC202006020"},{"key":"2026030517035207501_j_biol-2025-1285_ref_075","doi-asserted-by":"crossref","unstructured":"Talaat, RM, Mohamed, SF, Bassyouni, IH, Raouf, AA. Th1\/Th2\/Th17\/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine 2015;72:146\u201353. https:\/\/doi.org\/10.1016\/j.cyto.2014.12.027.","DOI":"10.1016\/j.cyto.2014.12.027"},{"key":"2026030517035207501_j_biol-2025-1285_ref_076","doi-asserted-by":"crossref","unstructured":"Zhang, YH, Chen, J, Mao, W-F, Yan, L-X, Long, F, Li, S-H, et al.. Harnessing miR-16-5p-Loaded exosomes from adipose-derived stem cells to restore immune homeostasis in SLE patients. Immunobiology 2025;230:152885. https:\/\/doi.org\/10.1016\/j.imbio.2025.152885.","DOI":"10.1016\/j.imbio.2025.152885"},{"key":"2026030517035207501_j_biol-2025-1285_ref_077","doi-asserted-by":"crossref","unstructured":"Zou, H, Ma, S, Li, L, Xia, X, Zhou, Y, Zhang, R. Downregulation of circular RNA ETS1 promotes SLE activity and inhibits Treg cell differentiation through miR-1205\/FoxP3 molecular axis. Int Immunopharmacol 2024;128:111539. https:\/\/doi.org\/10.1016\/j.intimp.2024.111539.","DOI":"10.1016\/j.intimp.2024.111539"},{"key":"2026030517035207501_j_biol-2025-1285_ref_078","doi-asserted-by":"crossref","unstructured":"Ma, S, Feng, G, Li, L, Li, Z, Zhou, X, Zhou, Y, et al.. Downregulation of circETS1 disrupts Th17\/Treg homeostasis by inhibiting FOXP3 transcription: a new potential biomarker in systemic lupus erythematosus. Lupus 2023;32:1430\u20139. https:\/\/doi.org\/10.1177\/09612033231207545.","DOI":"10.1177\/09612033231207545"},{"key":"2026030517035207501_j_biol-2025-1285_ref_079","doi-asserted-by":"crossref","unstructured":"Tu, J, Zheng, N, Mao, C, Liu, S, Zhang, H, Sun, L. UC-BSCs exosomes regulate Th17\/Treg balance in patients with systemic lupus erythematosus via miR-19b\/KLF13. Cells 2022;11:4123. https:\/\/doi.org\/10.3390\/cells11244123.","DOI":"10.3390\/cells11244123"},{"key":"2026030517035207501_j_biol-2025-1285_ref_080","doi-asserted-by":"crossref","unstructured":"Pan, Q, Gong, L, Xiao, H, Feng, Y, Li, L, Deng, Z, et al.. Basophil activation-dependent autoantibody and Interleukin-17 production exacerbate systemic lupus erythematosus. Front Immunol 2017;8:348. https:\/\/doi.org\/10.3389\/fimmu.2017.00348.","DOI":"10.3389\/fimmu.2017.00348"},{"key":"2026030517035207501_j_biol-2025-1285_ref_081","doi-asserted-by":"crossref","unstructured":"Goropev\u0161ek, A, Holcar, M, Av\u010din, T. The role of STAT signaling pathways in the pathogenesis of systemic lupus erythematosus. Clin Rev Allergy Immunol 2017;52:164\u201381. https:\/\/doi.org\/10.1007\/s12016-016-8550-y.","DOI":"10.1007\/s12016-016-8550-y"},{"key":"2026030517035207501_j_biol-2025-1285_ref_082","doi-asserted-by":"crossref","unstructured":"Yang, X, Yao, G, Chen, W, Tang, X, Feng, X, Sun, L. Exacerbation of lupus nephritis by high sodium chloride related to activation of SGK1 pathway. Int Immunopharmacol 2015;29:568\u201373. https:\/\/doi.org\/10.1016\/j.intimp.2015.09.027.","DOI":"10.1016\/j.intimp.2015.09.027"},{"key":"2026030517035207501_j_biol-2025-1285_ref_083","doi-asserted-by":"crossref","unstructured":"Wu, C, Yosef, N, Thalhamer, T, Zhu, C, Xiao, S, Kishi, Y, et al.. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 2013;496:513\u20137. https:\/\/doi.org\/10.1038\/nature11984.","DOI":"10.1038\/nature11984"},{"key":"2026030517035207501_j_biol-2025-1285_ref_084","doi-asserted-by":"crossref","unstructured":"Benfaremo, D, Tana, C, Moroncini, G. Pre-scleroderma and new opportunities for preventive medicine. Lancet Rheumatol 2024;6:e200. https:\/\/doi.org\/10.1016\/s2665-9913(24)00057-2.","DOI":"10.1016\/S2665-9913(24)00057-2"},{"key":"2026030517035207501_j_biol-2025-1285_ref_085","doi-asserted-by":"crossref","unstructured":"Kreuter, A, Moinzadeh, P, Kinberger, M, Horneff, G, Worm, M, Werner, RN, et al.. S2k guideline: diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges 2024;22:605\u201320. https:\/\/doi.org\/10.1111\/ddg.15328.","DOI":"10.1111\/ddg.15328"},{"key":"2026030517035207501_j_biol-2025-1285_ref_086","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly, S. Emerging therapeutic targets in systemic sclerosis. J\u00a0Mol Med (Berl) 2024;102:465\u201378. https:\/\/doi.org\/10.1007\/s00109-024-02424-w.","DOI":"10.1007\/s00109-024-02424-w"},{"key":"2026030517035207501_j_biol-2025-1285_ref_087","doi-asserted-by":"crossref","unstructured":"Freire, M, Sope\u00f1a, B, Gonz\u00e1lez-Quintela, A, Guill\u00e9n Del Castillo, A, Moraga, EC, Lled\u00f3-Iba\u00f1ez, GM, et al.. Exposure to different occupational chemicals and clinical phenotype of a cohort of patients with systemic sclerosis. Autoimmun Rev 2024;23:103542. https:\/\/doi.org\/10.1016\/j.autrev.2024.103542.","DOI":"10.1016\/j.autrev.2024.103542"},{"key":"2026030517035207501_j_biol-2025-1285_ref_088","doi-asserted-by":"crossref","unstructured":"Torok, KS, Li, SC, Jacobe, HM, Taber, SF, Stevens, AM, Zulian, F, et al.. Immunopathogenesis of pediatric localized scleroderma. Front Immunol 2019;10:908. https:\/\/doi.org\/10.3389\/fimmu.2019.00908.","DOI":"10.3389\/fimmu.2019.00908"},{"key":"2026030517035207501_j_biol-2025-1285_ref_089","doi-asserted-by":"crossref","unstructured":"Skaug, B, Khanna, D, Swindell, WR, Hinchcliff, ME, Frech, TM, Steen, VD, et al.. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis 2020;79:379\u201386. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215894.","DOI":"10.1136\/annrheumdis-2019-215894"},{"key":"2026030517035207501_j_biol-2025-1285_ref_090","doi-asserted-by":"crossref","unstructured":"Papara, C, De Luca, DA, Bieber, K, Vorobyev, A, Ludwig, RJ. Morphea: the 2023 update. Front Med (Lausanne) 2023;10:1108623. https:\/\/doi.org\/10.3389\/fmed.2023.1108623.","DOI":"10.3389\/fmed.2023.1108623"},{"key":"2026030517035207501_j_biol-2025-1285_ref_091","doi-asserted-by":"crossref","unstructured":"Almanzar, G, Klein, M, Schmalzing, M, Hilligardt, D, El Hajj, N, Kneitz, H, et al.. Disease manifestation and inflammatory activity as modulators of Th17\/Treg balance and RORC\/FoxP3 methylation in systemic sclerosis. Int Arch Allergy Immunol 2016;171:141\u201354. https:\/\/doi.org\/10.1159\/000450949.","DOI":"10.1159\/000450949"},{"key":"2026030517035207501_j_biol-2025-1285_ref_092","doi-asserted-by":"crossref","unstructured":"Sekiguchi, A, Shimokawa, C, Kato, T, Uchiyama, A, Yokoyama, Y, Ogino, S, et al.. Inhibition of skin fibrosis via regulation of Th17\/Treg imbalance in systemic sclerosis. Sci Rep 2025;15:1423. https:\/\/doi.org\/10.1038\/s41598-025-85895-2.","DOI":"10.1038\/s41598-025-85895-2"},{"key":"2026030517035207501_j_biol-2025-1285_ref_093","doi-asserted-by":"crossref","unstructured":"Amira, G, Akram, D, Fadoua, M, Bilel, N, Alya, B, Khalil, BS, et al.. Imbalance of TH17\/TREG cells in Tunisian patients with systemic sclerosis. Presse Med 2024;53:104221. https:\/\/doi.org\/10.1016\/j.lpm.2023.104221.","DOI":"10.1016\/j.lpm.2023.104221"},{"key":"2026030517035207501_j_biol-2025-1285_ref_094","doi-asserted-by":"crossref","unstructured":"Lu, Y, Zhao, C, Lei, L, Tao, Z, Zheng, L, Wen, J, et al.. Effects of thalidomide on Th17, Treg cells and TGF-\u03b21\/Smad3 pathway in a mouse model of systemic sclerosis. Int J Rheum Dis 2020;23:406\u201319. https:\/\/doi.org\/10.1111\/1756-185x.13769.","DOI":"10.1111\/1756-185X.13769"},{"key":"2026030517035207501_j_biol-2025-1285_ref_095","doi-asserted-by":"crossref","unstructured":"Um, IG, Woo, JS, Lee, YJ, Lee, SY, Jeong, HY, Na, HS, et al.. IL-21 drives skin and lung inflammation and fibrosis in a model for systemic sclerosis. Immunol Lett 2024;270:106924. https:\/\/doi.org\/10.1016\/j.imlet.2024.106924.","DOI":"10.1016\/j.imlet.2024.106924"},{"key":"2026030517035207501_j_biol-2025-1285_ref_096","doi-asserted-by":"crossref","unstructured":"Wang, C, Oishi, K, Kobayashi, T, Fujii, K, Horii, MN, Fushida, N, et al.. The role of TLR7 and TLR9 in the pathogenesis of systemic sclerosis. Int J Mol Sci 2024;25:6133. https:\/\/doi.org\/10.3390\/ijms25116133.","DOI":"10.3390\/ijms25116133"},{"key":"2026030517035207501_j_biol-2025-1285_ref_097","doi-asserted-by":"crossref","unstructured":"Wei, Y, Zhang, S, Shao, F, Sun, Y. Ankylosing spondylitis: from pathogenesis to therapy. Int Immunopharmacol 2025;145:113709. https:\/\/doi.org\/10.1016\/j.intimp.2024.113709.","DOI":"10.1016\/j.intimp.2024.113709"},{"key":"2026030517035207501_j_biol-2025-1285_ref_098","doi-asserted-by":"crossref","unstructured":"Rosine, N, Miceli-Richard, C. Innate cells: the alternative source of IL-17 in axial and peripheral spondyloarthritis? Front Immunol 2021;11:553742. https:\/\/doi.org\/10.3389\/fimmu.2020.553742.","DOI":"10.3389\/fimmu.2020.553742"},{"key":"2026030517035207501_j_biol-2025-1285_ref_099","doi-asserted-by":"crossref","unstructured":"Pishgahi, A, Abolhasan, R, Danaii, S, Amanifar, B, Soltani-Zangbar, MS, Zamani, M, et al.. Immunological and oxidative stress biomarkers in Ankylosing Spondylitis patients with or without metabolic syndrome. Cytokine 2020;128:155002. https:\/\/doi.org\/10.1016\/j.cyto.2020.155002.","DOI":"10.1016\/j.cyto.2020.155002"},{"key":"2026030517035207501_j_biol-2025-1285_ref_100","doi-asserted-by":"crossref","unstructured":"Su, Q-Y, Zheng, J-W, Yang, J-Y, Zhang, T-Y, Song, S, Zhao, R, et al.. Levels of peripheral Th17 cells and Th17-Related cytokines in patients with ankylosing spondylitis: a meta-analysis. Adv Ther 2022;39:4423\u201339. https:\/\/doi.org\/10.1007\/s12325-022-02240-z.","DOI":"10.1007\/s12325-022-02240-z"},{"key":"2026030517035207501_j_biol-2025-1285_ref_101","doi-asserted-by":"crossref","unstructured":"Liu, L, Yuan, Y, Zhang, S, Xu, J, Zou, J. Osteoimmunological insights into the pathogenesis of ankylosing spondylitis. J\u00a0Cell Physiol 2021;236:6090\u2013100. https:\/\/doi.org\/10.1002\/jcp.30313.","DOI":"10.1002\/jcp.30313"},{"key":"2026030517035207501_j_biol-2025-1285_ref_102","doi-asserted-by":"crossref","unstructured":"Liu, D, Liu, B, Gu, JC, Lin, J. Imbalance of peripheral lymphocyte subsets in patients with ankylosing spondylitis: a meta-analysis. Front Immunol 2021;12:696973. https:\/\/doi.org\/10.3389\/fimmu.2021.696973.","DOI":"10.3389\/fimmu.2021.696973"},{"key":"2026030517035207501_j_biol-2025-1285_ref_103","doi-asserted-by":"crossref","unstructured":"Fattahi, MJ, Ahmadi, H, Jafarnezhad-Ansariha, F, Mortazavi-Jahromi, SS, Rehm, BHA, Cuzzocrea, S, et al.. Oral administration effects of \u03b2-d-mannuronic acid (M2000) on Th17 and regulatory T\u00a0cells in patients with ankylosing spondylitis. Biomed Pharmacother 2018;100:495\u2013500. https:\/\/doi.org\/10.1016\/j.biopha.2018.02.059.","DOI":"10.1016\/j.biopha.2018.02.059"},{"key":"2026030517035207501_j_biol-2025-1285_ref_104","doi-asserted-by":"crossref","unstructured":"Groen, SS, Sinkeviciute, D, Bay-Jensen, A-C, Thudium, CS, Karsdal, MA, Thomsen, SF, et al.. Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers. Autoimmun Rev 2021;20:102760. https:\/\/doi.org\/10.1016\/j.autrev.2021.102760.","DOI":"10.1016\/j.autrev.2021.102760"},{"key":"2026030517035207501_j_biol-2025-1285_ref_105","doi-asserted-by":"crossref","unstructured":"Wang, C, Liao, Q, Hu, Y, Zhong, DA. T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis. Exp Ther Med 2015;9:250\u20136. https:\/\/doi.org\/10.3892\/etm.2014.2046.","DOI":"10.3892\/etm.2014.2046"},{"key":"2026030517035207501_j_biol-2025-1285_ref_106","doi-asserted-by":"crossref","unstructured":"Xue, YL, Lina, C, Zhenbiao, W, Qing, H, Qiang, L, Zhu, P. Levels of circulating Th17 cells and regulatory T\u00a0cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-\u03b1 therapy. J\u00a0Clin Immunol 2013;33:151\u201361. https:\/\/doi.org\/10.1007\/s10875-012-9774-0.","DOI":"10.1007\/s10875-012-9774-0"},{"key":"2026030517035207501_j_biol-2025-1285_ref_107","doi-asserted-by":"crossref","unstructured":"Xie, J, Wang, Z, Wang, W. Semaphorin 4D induces an imbalance of Th17\/Treg cells by activating the aryl hydrocarbon receptor in ankylosing spondylitis. Front Immunol 2020;11:2151. https:\/\/doi.org\/10.3389\/fimmu.2020.02151.","DOI":"10.3389\/fimmu.2020.02151"},{"key":"2026030517035207501_j_biol-2025-1285_ref_108","doi-asserted-by":"crossref","unstructured":"Xu, F, Guang, C, Liang, Y, Jun, W, Wei, W, Bao, H. Treg-promoted new bone formation through suppressing TH17 by secreting Interleukin-10 in ankylosing spondylitis. Spine 2019;44.","DOI":"10.1097\/BRS.0000000000003169"},{"key":"2026030517035207501_j_biol-2025-1285_ref_109","doi-asserted-by":"crossref","unstructured":"Lykhopiy, V, Malviya, V, Humblet-Baron, S, Schlenner, SM. IL-2 immunotherapy for targeting regulatory T\u00a0cells in autoimmunity. Genes Immun 2023;24:248\u201362. https:\/\/doi.org\/10.1038\/s41435-023-00221-y.","DOI":"10.1038\/s41435-023-00221-y"},{"key":"2026030517035207501_j_biol-2025-1285_ref_110","doi-asserted-by":"crossref","unstructured":"Dean, EC, Ditoro, DF, Pham, D, Gao, M, Zindl, CL, Frey, B, et al.. IL-2-induced Stat3 signaling is critical for effector Treg cell programming. bioRxiv 2023;2023:559434. https:\/\/doi.org\/10.1101\/2023.09.26.559434.","DOI":"10.1101\/2023.09.26.559434"},{"key":"2026030517035207501_j_biol-2025-1285_ref_111","doi-asserted-by":"crossref","unstructured":"Wang, J, Zhang, SX, Chang, J-S, Cheng, T, Jiang, XJ, Su, QY, et al.. Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T\u00a0cells in patients with refractory rheumatoid arthritis: a randomized controlled trial. Front Immunol 2022;13:947341. https:\/\/doi.org\/10.3389\/fimmu.2022.947341.","DOI":"10.3389\/fimmu.2022.947341"},{"key":"2026030517035207501_j_biol-2025-1285_ref_112","doi-asserted-by":"crossref","unstructured":"Zhang, SX, Wang, J, Wang, CH, Jia, RH, Yan, M, Hu, FY, et al.. Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T\u00a0cells in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2021;13:1759720X211011370. https:\/\/doi.org\/10.1177\/1759720x211011370.","DOI":"10.21203\/rs.3.rs-93717\/v1"},{"key":"2026030517035207501_j_biol-2025-1285_ref_113","doi-asserted-by":"crossref","unstructured":"Yan, H, Zi, X, Yan, H, Zhang, X, Bai, J, Gao, C, et al.. The absolute number of circulating Treg cells is reduced in difficult-to-treat RA patients and is ameliorated by low-dose IL-2. Front Immunol 2025;16:1522893. https:\/\/doi.org\/10.3389\/fimmu.2025.1522893.","DOI":"10.3389\/fimmu.2025.1522893"},{"key":"2026030517035207501_j_biol-2025-1285_ref_114","doi-asserted-by":"crossref","unstructured":"Miao, M, Hao, Z, Guo, Y, Zhang, X, Zhang, S, Luo, J, et al.. Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 2018;77:1838\u201340. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213036.","DOI":"10.1136\/annrheumdis-2018-213036"},{"key":"2026030517035207501_j_biol-2025-1285_ref_115","doi-asserted-by":"crossref","unstructured":"He, J, Chen, J, Miao, M, Zhang, R, Cheng, G, Wang, Y, et al.. Efficacy and safety of low-dose interleukin 2 for primary sj\u00f6gren syndrome: a randomized clinical trial. JAMA Netw Open 2022;5:e2241451. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.41451.","DOI":"10.1001\/jamanetworkopen.2022.41451"},{"key":"2026030517035207501_j_biol-2025-1285_ref_116","doi-asserted-by":"crossref","unstructured":"Feng, R, Xiao, X, Wang, Y, Huang, B, Chen, J, Cheng, G, et al.. Metabolic impact of low dose IL-2 therapy for primary Sj\u00f6gren\u2019s syndrome in a double-blind, randomized clinical trial. Clin Rheumatol 2024;43:3789\u201398. https:\/\/doi.org\/10.1007\/s10067-024-07165-2.","DOI":"10.1007\/s10067-024-07165-2"},{"key":"2026030517035207501_j_biol-2025-1285_ref_117","doi-asserted-by":"crossref","unstructured":"Zhou, H, Zhao, X, Zhang, R, Miao, M, Pei, W, Li, Z, et al.. Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE. Signal Transduct Target Ther 2023;8:141. https:\/\/doi.org\/10.1038\/s41392-023-01350-6.","DOI":"10.1038\/s41392-023-01350-6"},{"key":"2026030517035207501_j_biol-2025-1285_ref_118","doi-asserted-by":"crossref","unstructured":"Hao, H, Nakayamada, S, Yamagata, K, Ohkubo, N, Iwata, S, Inoue, Y, et al.. Conversion of T follicular helper cells to T follicular regulatory cells by Interleukin-2 through transcriptional regulation in systemic lupus erythematosus. Arthritis Rheumatol 2021;73:132\u201342. https:\/\/doi.org\/10.1002\/art.41457.","DOI":"10.1002\/art.41457"},{"key":"2026030517035207501_j_biol-2025-1285_ref_119","doi-asserted-by":"crossref","unstructured":"Zhou, P, Chen, J, He, J, Zheng, T, Yunis, J, Makota, V, et al.. Low-dose IL-2 therapy invigorates CD8+ T\u00a0cells for viral control in systemic lupus erythematosus. PLoS Pathog 2021;17:e1009858. https:\/\/doi.org\/10.1371\/journal.ppat.1009858.","DOI":"10.1371\/journal.ppat.1009858"},{"key":"2026030517035207501_j_biol-2025-1285_ref_120","doi-asserted-by":"crossref","unstructured":"Rosenzwajg, M, Lorenzon, R, Cacoub, P, Pham, HP, Pitoiset, F, El Soufi, K, et al.. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis 2019;78:209\u201317. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214229.","DOI":"10.1136\/annrheumdis-2018-214229"},{"key":"2026030517035207501_j_biol-2025-1285_ref_121","doi-asserted-by":"crossref","unstructured":"Ghoreschi, K, Balato, A, Enerb\u00e4ck, C, Sabat, R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 2021;397:754\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(21)00184-7.","DOI":"10.1016\/S0140-6736(21)00184-7"},{"key":"2026030517035207501_j_biol-2025-1285_ref_122","doi-asserted-by":"crossref","unstructured":"McGeachy, MJ, Cua, DJ, Gaffen, SL. The IL-17 family of cytokines in health and disease. Immunity 2019;50:892\u2013906. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.021.","DOI":"10.1016\/j.immuni.2019.03.021"},{"key":"2026030517035207501_j_biol-2025-1285_ref_123","doi-asserted-by":"crossref","unstructured":"Tam, H, Robinson, P, Nash, P. Inhibiting IL-17A and IL-17F in rheumatic disease: therapeutics help to elucidate disease mechanisms. Curr Rheumatol Rep 2022;24:310\u201320. https:\/\/doi.org\/10.1007\/s11926-022-01084-4.","DOI":"10.1007\/s11926-022-01084-4"},{"key":"2026030517035207501_j_biol-2025-1285_ref_124","doi-asserted-by":"crossref","unstructured":"Adams, R, Maroof, A, Baker, T, Lawson, ADG, Oliver, R, Paveley, R, et al.. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol 2020;11:1894. https:\/\/doi.org\/10.3389\/fimmu.2020.01894.","DOI":"10.3389\/fimmu.2020.01894"},{"key":"2026030517035207501_j_biol-2025-1285_ref_125","doi-asserted-by":"crossref","unstructured":"Kolbinger, F, Di Padova, F, Deodhar, A, Hawkes, JE, Huppertz, C, Kuiper, T, et al.. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacol Ther 2022;229:107925. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107925.","DOI":"10.1016\/j.pharmthera.2021.107925"},{"key":"2026030517035207501_j_biol-2025-1285_ref_126","doi-asserted-by":"crossref","unstructured":"Yiu, ZZN, Mason, KJ, Hampton, PJ, Reynolds, NJ, Smith, CH, Lunt, M, et al.. Randomized trial replication using observational data for comparative effectiveness of secukinumab and ustekinumab in psoriasis: a study from the British association of dermatologists biologics and immunomodulators register. JAMA Dermatol 2021;157:66\u201373. https:\/\/doi.org\/10.1001\/jamadermatol.2020.4202.","DOI":"10.1001\/jamadermatol.2020.4202"},{"key":"2026030517035207501_j_biol-2025-1285_ref_127","doi-asserted-by":"crossref","unstructured":"Hk, M, Kim, H, Lee, S, Hong, Y, Kim, M, Park, S, et al.. Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure. Rheumatology (Oxford, England) 2021;60.","DOI":"10.1093\/rheumatology\/keab245"},{"key":"2026030517035207501_j_biol-2025-1285_ref_128","doi-asserted-by":"crossref","unstructured":"Blair, HA. Correction to: secukinumab: a review in ankylosing spondylitis. Drugs 2019;79:445. https:\/\/doi.org\/10.1007\/s40265-019-01089-x.","DOI":"10.1007\/s40265-019-01089-x"},{"key":"2026030517035207501_j_biol-2025-1285_ref_129","doi-asserted-by":"crossref","unstructured":"Rauseo Vera, M, Guti\u00e9rrez-Gonz\u00e1lez, L, Maldonado, I, Al Snih, S. Validity of a Venezuelan version of the Bath ankylosing spondylitis functional index and Bath ankylosing spondylitis disease activity index. Reumatol Cl\u00ednica 2019;15:223\u20138. https:\/\/doi.org\/10.1016\/j.reuma.2017.08.002.","DOI":"10.1016\/j.reumae.2017.08.006"},{"key":"2026030517035207501_j_biol-2025-1285_ref_130","doi-asserted-by":"crossref","unstructured":"Baraliakos, X, Gossec, L, Pournara, E, Jeka, S, Mera-Varela, A, D\u2019Angelo, S, et al.. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 2021;80:582\u201390. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218808.","DOI":"10.1136\/annrheumdis-2020-218808"},{"key":"2026030517035207501_j_biol-2025-1285_ref_131","unstructured":"Farah Izati, A, Wong, KK, Che Maraina, CH. IL-23\/IL-17 axis in the pathogenesis and treatment of systemic lupus erythematosus and rheumatoid arthritis. Malays J Pathol 2020;42:333\u201347."},{"key":"2026030517035207501_j_biol-2025-1285_ref_132","doi-asserted-by":"crossref","unstructured":"Schwarz, T, Almanzar, G, Wulfheide, M, Woidich, R, Holzer, M-T, Christoforou, T, et al.. Influence of a Th17-Inducing cytokine milieu on phenotypical and functional properties of regulatory T\u00a0cells in chronic inflammatory arthritis. Int J Mol Sci 2025;26:7339. https:\/\/doi.org\/10.3390\/ijms26157339.","DOI":"10.3390\/ijms26157339"},{"key":"2026030517035207501_j_biol-2025-1285_ref_133","doi-asserted-by":"crossref","unstructured":"Gelinas, A, Powell, J, Lapointe, C, Coulombe, J. Segmental stiff skin syndrome treated with secukinumab. Pediatr Dermatol 2023;40:738\u20139. https:\/\/doi.org\/10.1111\/pde.15274.","DOI":"10.1111\/pde.15274"},{"key":"2026030517035207501_j_biol-2025-1285_ref_134","doi-asserted-by":"crossref","unstructured":"Marinho, A, Delgado Alves, J, Fortuna, J, Faria, R, Almeida, I, Alves, G, et al.. Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sj\u00f6gren\u2019s syndrome: evidence- and practice-based guidance. Front Immunol 2023;14:1117699. https:\/\/doi.org\/10.3389\/fimmu.2023.1117699.","DOI":"10.3389\/fimmu.2023.1117699"},{"key":"2026030517035207501_j_biol-2025-1285_ref_135","doi-asserted-by":"crossref","unstructured":"Saran, A, Nishizaki, D, Lippman, SM, Kato, S, Kurzrock, R. Interleukin-17: a pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders. Cytokine Growth Factor Rev 2025;83:35\u201344. https:\/\/doi.org\/10.1016\/j.cytogfr.2025.01.002.","DOI":"10.1016\/j.cytogfr.2025.01.002"},{"key":"2026030517035207501_j_biol-2025-1285_ref_136","doi-asserted-by":"crossref","unstructured":"Chandran, V, Van der Heijde, D, Rm, F, Lespessailles, E, Helliwell, P, Kameda, H, et al.. Ixekizumab treatment of biologic-na\u00efve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology (Oxford, England) 2020;59.","DOI":"10.1093\/rheumatology\/kez684"},{"key":"2026030517035207501_j_biol-2025-1285_ref_137","doi-asserted-by":"crossref","unstructured":"Coates, L, Pillai, S, Tahir, H, Valter, I, Chandran, V, Kameda, H, et al.. Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study. Arthritis Rheumatol (Hoboken, NJ) 2021;73:1663\u201372. https:\/\/doi.org\/10.1002\/art.41716.","DOI":"10.1002\/art.41716"},{"key":"2026030517035207501_j_biol-2025-1285_ref_138","doi-asserted-by":"crossref","unstructured":"Craig, S, Warren, RB. Ixekizumab for the treatment of psoriasis: up-to-date. Expert Opin Biol Ther 2020;20:549\u201357. https:\/\/doi.org\/10.1080\/14712598.2020.1729736.","DOI":"10.1080\/14712598.2020.1729736"},{"key":"2026030517035207501_j_biol-2025-1285_ref_139","doi-asserted-by":"crossref","unstructured":"Deodhar, AA, Combe, B, Accioly, AP, Bolce, R, Zhu, D, Gellett, AM, et al.. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000\u00a0patient-years of exposure. Ann Rheum Dis 2022;81:944\u201350. https:\/\/doi.org\/10.1136\/annrheumdis-2021-222027.","DOI":"10.1136\/annrheumdis-2021-222027"},{"key":"2026030517035207501_j_biol-2025-1285_ref_140","doi-asserted-by":"crossref","unstructured":"Garbers, C, Heink, S, Korn, T, Rose-John, S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov 2018;17:395\u2013412. https:\/\/doi.org\/10.1038\/nrd.2018.45.","DOI":"10.1038\/nrd.2018.45"},{"key":"2026030517035207501_j_biol-2025-1285_ref_141","doi-asserted-by":"crossref","unstructured":"Choy, EH, De Benedetti, F, Takeuchi, T, Hashizume, M, John, MR, Kishimoto, T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 2020;16:335\u201345. https:\/\/doi.org\/10.1038\/s41584-020-0419-z.","DOI":"10.1038\/s41584-020-0419-z"},{"key":"2026030517035207501_j_biol-2025-1285_ref_142","doi-asserted-by":"crossref","unstructured":"Zormpa, T, Thireou, T, Beloukas, A, Chaniotis, D, Golfinopoulou, R, Vlachakis, D, et al.. The genetic background of ankylosing spondylitis reveals a distinct overlap with autoimmune diseases: a systematic review. J\u00a0Clin Med 2025;14:3677. https:\/\/doi.org\/10.3390\/jcm14113677.","DOI":"10.3390\/jcm14113677"},{"key":"2026030517035207501_j_biol-2025-1285_ref_143","doi-asserted-by":"crossref","unstructured":"Kang, S, Tanaka, T, Inoue, H, Ono, C, Hashimoto, S, Kioi, Y, et al.. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci USA 2020;117:22351\u20136. https:\/\/doi.org\/10.1073\/pnas.2010229117.","DOI":"10.1073\/pnas.2010229117"},{"key":"2026030517035207501_j_biol-2025-1285_ref_144","doi-asserted-by":"crossref","unstructured":"Ishikawa, Y, Hattori, K, Ishikawa, J, Fujiwara, M, Kita, Y. Refractory Sj\u00f6gren\u2019s syndrome myelopathy successfully treated with subcutaneous tocilizumab: a case report. Medicine (Baltim) 2019;98:e16285. https:\/\/doi.org\/10.1097\/md.0000000000016285.","DOI":"10.1097\/MD.0000000000016285"},{"key":"2026030517035207501_j_biol-2025-1285_ref_145","doi-asserted-by":"crossref","unstructured":"Bouajina, E, Zakraoui, L, Kchir, M, Kochbati, S, Baklouti, S. Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice. Clin Rheumatol 2020;39:1449\u201355. https:\/\/doi.org\/10.1007\/s10067-019-04815-8.","DOI":"10.1007\/s10067-019-04815-8"},{"key":"2026030517035207501_j_biol-2025-1285_ref_146","doi-asserted-by":"crossref","unstructured":"Ding, C, Cicuttini, F, Li, J, Jones, G. Targeting IL-6 in the treatment of inflammatory and autoimmune diseases. Expert Opin Investig Drugs 2009;18:1457\u201366. https:\/\/doi.org\/10.1517\/13543780903203789.","DOI":"10.1517\/13543780903203789"},{"key":"2026030517035207501_j_biol-2025-1285_ref_147","doi-asserted-by":"crossref","unstructured":"Felten, R, Devauchelle-Pensec, V, Seror, R, Duffau, P, Saadoun, D, Hachulla, E, et al.. Interleukin 6 receptor inhibition in primary sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis 2021;80:329\u201338. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218467.","DOI":"10.1136\/annrheumdis-2020-218467"},{"key":"2026030517035207501_j_biol-2025-1285_ref_148","doi-asserted-by":"crossref","unstructured":"Justet, A, Ottaviani, S, Dieud\u00e9, P, Taill\u00e9, C. Tocilizumab for refractory organising pneumonia associated with Sj\u00f6gren\u2019s disease. BMJ Case Rep 2015;2015:bcr2014209076. https:\/\/doi.org\/10.1136\/bcr-2014-209076.","DOI":"10.1136\/bcr-2014-209076"},{"key":"2026030517035207501_j_biol-2025-1285_ref_149","doi-asserted-by":"crossref","unstructured":"Hsu, H-C, Chen, Y-H, Lin, T-S, Shen, C-Y, Hsieh, S-C. Systemic lupus erythematosus is associated with impaired autophagic degradation via interleukin-6 in macrophages. Biochim Biophys Acta Mol Basis Dis 2021;1867:166027. https:\/\/doi.org\/10.1016\/j.bbadis.2020.166027.","DOI":"10.1016\/j.bbadis.2020.166027"},{"key":"2026030517035207501_j_biol-2025-1285_ref_150","doi-asserted-by":"crossref","unstructured":"Sieper, J, Porter-Brown, B, Thompson, L, Harari, O, Dougados, M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 2014;73:95\u2013100. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203559.","DOI":"10.1136\/annrheumdis-2013-203559"},{"key":"2026030517035207501_j_biol-2025-1285_ref_151","doi-asserted-by":"crossref","unstructured":"Sheng, XR, Gao, X, Schiffman, C, Jiang, J, Ramalingam, TR, Lin, CJF, et al.. Biomarkers of fibrosis, inflammation, and extracellular matrix in the phase 3 trial of tocilizumab in systemic sclerosis. Clin Immunol 2023;254:109695. https:\/\/doi.org\/10.1016\/j.clim.2023.109695.","DOI":"10.1016\/j.clim.2023.109695"},{"key":"2026030517035207501_j_biol-2025-1285_ref_152","doi-asserted-by":"crossref","unstructured":"Khanna, D, Lin, CJF, Furst, DE, Goldin, J, Kim, G, Kuwana, M, et al.. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2020;8:963\u201374. https:\/\/doi.org\/10.1016\/s2213-2600(20)30318-0.","DOI":"10.1016\/S2213-2600(20)30318-0"},{"key":"2026030517035207501_j_biol-2025-1285_ref_153","doi-asserted-by":"crossref","unstructured":"Taylor, PC, Weinblatt, ME, McInnes, IB, Atsumi, T, Strand, V, Takeuchi, T, et al.. Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3). Ann Rheum Dis 2023;82:1527\u201337. https:\/\/doi.org\/10.1136\/ard-2023-224449.","DOI":"10.1136\/ard-2023-224449"},{"key":"2026030517035207501_j_biol-2025-1285_ref_154","doi-asserted-by":"crossref","unstructured":"Wang, M, Chen, L, He, J, Xia, W, Ye, Z, She, J. Structural insights into IL-6 signaling inhibition by therapeutic antibodies. Cell Rep 2024;43:113819. https:\/\/doi.org\/10.1016\/j.celrep.2024.113819.","DOI":"10.1016\/j.celrep.2024.113819"},{"key":"2026030517035207501_j_biol-2025-1285_ref_155","doi-asserted-by":"crossref","unstructured":"Sieper, J, Braun, J, Kay, J, Badalamenti, S, Radin, AR, Jiao, L, et al.. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 2015;74:1051\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204963.","DOI":"10.1136\/annrheumdis-2013-204963"},{"key":"2026030517035207501_j_biol-2025-1285_ref_156","doi-asserted-by":"crossref","unstructured":"Zhao, MY, Zhang, W, Rao, GW. Targeting Janus kinase (JAK) for fighting diseases: the research of JAK inhibitor drugs. Curr Med Chem 2022;29:5010\u201340. https:\/\/doi.org\/10.2174\/1568026622666220307124142.","DOI":"10.2174\/1568026622666220307124142"},{"key":"2026030517035207501_j_biol-2025-1285_ref_157","doi-asserted-by":"crossref","unstructured":"Wang, L, Lee, YH, Yang, XL, Shih, PC, Gao, JF, Zhang, LY. The safety and efficacy of JAK inhibitors: have we found the right pathway? Int J Rheum Dis 2025;28:e70130. https:\/\/doi.org\/10.1111\/1756-185x.70130.","DOI":"10.1111\/1756-185X.70130"},{"key":"2026030517035207501_j_biol-2025-1285_ref_158","doi-asserted-by":"crossref","unstructured":"Owen, KL, Brockwell, NK, Parker, BS. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers (Basel) 2019;11:2002. https:\/\/doi.org\/10.3390\/cancers11122002.","DOI":"10.3390\/cancers11122002"},{"key":"2026030517035207501_j_biol-2025-1285_ref_159","doi-asserted-by":"crossref","unstructured":"Wei, XH, Liu, YY. Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy. Front Pharmacol 2023;14:1326281. https:\/\/doi.org\/10.3389\/fphar.2023.1326281.","DOI":"10.3389\/fphar.2023.1326281"},{"key":"2026030517035207501_j_biol-2025-1285_ref_160","doi-asserted-by":"crossref","unstructured":"Ozdede, A, Yaz\u0131c\u0131, H. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N\u00a0Engl J Med 2022;386:1766. https:\/\/doi.org\/10.1056\/NEJMc2202778.","DOI":"10.1056\/NEJMc2202778"},{"key":"2026030517035207501_j_biol-2025-1285_ref_161","doi-asserted-by":"crossref","unstructured":"U S Food and Drug Administration. Food and drug Administration\u2019s safe use initiative collaborating to reduce preventable harm from medications. J\u00a0Pain Palliat Care Pharmacother 2010;24:76\u201393. https:\/\/doi.org\/10.3109\/15360280903583214.","DOI":"10.3109\/15360280903583214"},{"key":"2026030517035207501_j_biol-2025-1285_ref_162","doi-asserted-by":"crossref","unstructured":"Richter, P, Cardoneanu, A, Burlui, AM, Macovei, L, Bratoiu, I, Buliga-Finis, ON, et al.. Why do we need JAK inhibitors in systemic lupus erythematosus? Int J Mol Sci 2022;23:11788. https:\/\/doi.org\/10.3390\/ijms231911788.","DOI":"10.3390\/ijms231911788"},{"key":"2026030517035207501_j_biol-2025-1285_ref_163","doi-asserted-by":"crossref","unstructured":"Bonnardeaux, E, Dutz, JP. Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep 2022;20:61\u20134. https:\/\/doi.org\/10.1016\/j.jdcr.2021.09.030.","DOI":"10.1016\/j.jdcr.2021.09.030"},{"key":"2026030517035207501_j_biol-2025-1285_ref_164","doi-asserted-by":"crossref","unstructured":"Karatas, A, Oz, B, Celik, C, Akar, ZA, Akkoc, RF, Etem, EO, et al.. Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis. Sci Rep 2022;12:2553. https:\/\/doi.org\/10.1038\/s41598-022-06581-1.","DOI":"10.1038\/s41598-022-06581-1"},{"key":"2026030517035207501_j_biol-2025-1285_ref_165","doi-asserted-by":"crossref","unstructured":"You, H, Xu, D, Hou, Y, Zhou, J, Wang, Q, Li, M, et al.. Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 2021;60:2472\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keaa613.","DOI":"10.1093\/rheumatology\/keaa613"},{"key":"2026030517035207501_j_biol-2025-1285_ref_166","doi-asserted-by":"crossref","unstructured":"Cheng, L, Chen, J, Rong, X. Mechanism of emodin in the treatment of rheumatoid arthritis. Evid Based Complement Alternat Med 2022;2022:9482570. https:\/\/doi.org\/10.1155\/2022\/9482570.","DOI":"10.1155\/2022\/9482570"},{"key":"2026030517035207501_j_biol-2025-1285_ref_167","doi-asserted-by":"crossref","unstructured":"Hammaker, D, Nygaard, G, Kuhs, A, Ai, R, Boyle, DL, Wang, W, et al.. Joint location-specific JAK-STAT signaling in rheumatoid arthritis fibroblast-like synoviocytes. ACR Open Rheumatol 2019;1:640\u20138. https:\/\/doi.org\/10.1002\/acr2.11093.","DOI":"10.1002\/acr2.11093"},{"key":"2026030517035207501_j_biol-2025-1285_ref_168","doi-asserted-by":"crossref","unstructured":"Wollenhaupt, J, Lee, EB, Curtis, JR, Silverfield, J, Terry, K, Soma, K, et al.. Safety and efficacy of tofacitinib for up to 9.5\u00a0years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 2019;21:89. https:\/\/doi.org\/10.1186\/s13075-019-1866-2.","DOI":"10.1186\/s13075-019-1866-2"},{"key":"2026030517035207501_j_biol-2025-1285_ref_169","doi-asserted-by":"crossref","unstructured":"Hou, L, Zhou, P, Zhao, C, Wang, X, Du, Y. Tofacitinib for child-onset systemic lupus erythematosus. Front Immunol 2024;15:1457\u2013821. https:\/\/doi.org\/10.3389\/fimmu.2024.1457821.","DOI":"10.3389\/fimmu.2024.1457821"},{"key":"2026030517035207501_j_biol-2025-1285_ref_170","doi-asserted-by":"crossref","unstructured":"Ceobanu, G, Edwards, CJ. JAK inhibitors in systemic lupus erythematosus: translating pathogenesis into therapy. Lupus 2024;33:1403\u201315. https:\/\/doi.org\/10.1177\/09612033241287594.","DOI":"10.1177\/09612033241287594"},{"key":"2026030517035207501_j_biol-2025-1285_ref_171","doi-asserted-by":"crossref","unstructured":"Zhou, KY, Ye, Q, Fang, S. Nodular scleroderma partially controlled with tofacitinib. An Bras Dermatol 2024;99:989\u201391. https:\/\/doi.org\/10.1016\/j.abd.2024.02.003.","DOI":"10.1016\/j.abd.2024.02.003"},{"key":"2026030517035207501_j_biol-2025-1285_ref_172","doi-asserted-by":"crossref","unstructured":"Mv, P, Maikap, D, Padhan, P. Successful use of tofacitinib in scleroderma arthropathy. Mediterr J Rheumatol. 2023;34:266\u20138. https:\/\/doi.org\/10.31138\/mjr.34.2.266.","DOI":"10.31138\/mjr.34.2.266"},{"key":"2026030517035207501_j_biol-2025-1285_ref_173","doi-asserted-by":"crossref","unstructured":"Karalilova, RV, Batalov, ZA, Sapundzhieva, TL, Matucci-Cerinic, M, Batalov, AZ. Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound. Rheumatol Int 2021;41:1743\u201353. https:\/\/doi.org\/10.1007\/s00296-021-04956-7.","DOI":"10.1007\/s00296-021-04956-7"},{"key":"2026030517035207501_j_biol-2025-1285_ref_174","doi-asserted-by":"crossref","unstructured":"Liu, Q, Zeng, Y, Xing, X, Huang, B, Feng, R, Wang, Y, et al.. Evaluating the therapeutic potential of tofacitinib in Sj\u00f6gren\u2019s disease: a comprehensive clinical and immunological assessment. Rheumatology (Oxford) 2025;64:5899\u2013910. https:\/\/doi.org\/10.1093\/rheumatology\/keaf173.","DOI":"10.1093\/rheumatology\/keaf173"},{"key":"2026030517035207501_j_biol-2025-1285_ref_175","doi-asserted-by":"crossref","unstructured":"Barrera, M-J, Aguilera, S, Castro, I, Matus, S, Carvajal, P, Molina, C, et al.. Tofacitinib counteracts IL-6 overexpression induced by deficient autophagy: implications in Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford) 2021;60:1951\u201362. https:\/\/doi.org\/10.1093\/rheumatology\/keaa670.","DOI":"10.1093\/rheumatology\/keaa670"},{"key":"2026030517035207501_j_biol-2025-1285_ref_176","doi-asserted-by":"crossref","unstructured":"Ciobanu, DA, Poenariu, IS, Cr\u00eengu\u015f, L, Vreju, FA, Turcu-Stiolica, A, Tica, AA, et al.. JAK\/STAT pathway in pathology of rheumatoid arthritis (Review). Exp Ther Med 2020;20.","DOI":"10.3892\/etm.2020.8982"},{"key":"2026030517035207501_j_biol-2025-1285_ref_177","doi-asserted-by":"crossref","unstructured":"Markham, A. Baricitinib: first global approval. Drugs 2017;77:697\u2013704. https:\/\/doi.org\/10.1007\/s40265-017-0723-3.","DOI":"10.1007\/s40265-017-0723-3"},{"key":"2026030517035207501_j_biol-2025-1285_ref_178","doi-asserted-by":"crossref","unstructured":"D\u00f6rner, T, Tanaka, Y, Dow, ER, Koch, AE, Silk, M, Ross Terres, JA, et al.. Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Ann Rheum Dis 2022;81:1267\u201372. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222335.","DOI":"10.1136\/annrheumdis-2022-222335"},{"key":"2026030517035207501_j_biol-2025-1285_ref_179","doi-asserted-by":"crossref","unstructured":"Lee, J, Park, Y, Jang, SG, Hong, S-M, Song, Y-S, Kim, M-J, et al.. Baricitinib attenuates autoimmune phenotype and podocyte injury in a murine model of systemic lupus erythematosus. Front Immunol 2021;12:704526. https:\/\/doi.org\/10.3389\/fimmu.2021.704526.","DOI":"10.3389\/fimmu.2021.704526"},{"key":"2026030517035207501_j_biol-2025-1285_ref_180","doi-asserted-by":"crossref","unstructured":"Morand, EF, Vital, EM, Petri, M, van Vollenhoven, R, Wallace, DJ, Mosca, M, et al.. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 2023;401:1001\u201310. https:\/\/doi.org\/10.1016\/s0140-6736(22)02607-1.","DOI":"10.1016\/S0140-6736(22)02607-1"},{"key":"2026030517035207501_j_biol-2025-1285_ref_181","doi-asserted-by":"crossref","unstructured":"Kie\u0142bowski, K, Plewa, P, Bratborska, AW, Bakinowska, E, Pawlik, A. JAK inhibitors in rheumatoid arthritis: immunomodulatory properties and clinical efficacy. Int J Mol Sci 2024;25:8327. https:\/\/doi.org\/10.3390\/ijms25158327.","DOI":"10.3390\/ijms25158327"},{"key":"2026030517035207501_j_biol-2025-1285_ref_182","doi-asserted-by":"crossref","unstructured":"Chikhoune, L, Poggi, C, Moreau, J, Dubucquoi, S, Hachulla, E, Collet, A, et al.. JAK inhibitors (JAKi): mechanisms of action and perspectives in systemic and autoimmune diseases. Rev Med Interne 2025;46:89\u2013106. https:\/\/doi.org\/10.1016\/j.revmed.2024.10.452.","DOI":"10.1016\/j.revmed.2024.10.452"},{"key":"2026030517035207501_j_biol-2025-1285_ref_183","doi-asserted-by":"crossref","unstructured":"Burmester, GR, Kremer, JM, Van den Bosch, F, Kivitz, A, Bessette, L, Li, Y, et al.. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:2503\u201312. https:\/\/doi.org\/10.1016\/s0140-6736(18)31115-2.","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"2026030517035207501_j_biol-2025-1285_ref_184","doi-asserted-by":"crossref","unstructured":"\u015eener, S, \u015eener, YZ, Batu, ED, Sari, A, Akdo\u011fan, A. Janus kinase inhibitors in localized scleroderma: a systematic literature review. Turk J Med Sci 2025;55:533\u20139, https:\/\/doi.org\/10.55730\/1300-0144.6000.","DOI":"10.55730\/1300-0144.6000"},{"key":"2026030517035207501_j_biol-2025-1285_ref_185","doi-asserted-by":"crossref","unstructured":"Bai, W, Liu, H, Dou, L, Yang, Y, Leng, X, Li, M, et al.. Pilot study of baricitinib for active Sjogren\u2019s syndrome. Ann Rheum Dis 2022;81:1050\u20132. https:\/\/doi.org\/10.1136\/annrheumdis-2021-222053.","DOI":"10.1136\/annrheumdis-2021-222053"},{"key":"2026030517035207501_j_biol-2025-1285_ref_186","doi-asserted-by":"crossref","unstructured":"Aota, K, Yamanoi, T, Kani, K, Ono, S, Momota, Y, Azuma, M. Inhibition of JAK-STAT signaling by baricitinib reduces Interferon-\u03b3-Induced CXCL10 production in human salivary gland ductal cells. Inflammation 2021;44:206\u201316. https:\/\/doi.org\/10.1007\/s10753-020-01322-w.","DOI":"10.1007\/s10753-020-01322-w"},{"key":"2026030517035207501_j_biol-2025-1285_ref_187","doi-asserted-by":"crossref","unstructured":"Garrido, I, Lopes, S, Macedo, G. Hit the road JAK! the role of new oral treatment in inflammatory bowel disease. Inflamm Bowel Dis 2021;27:2010\u201322. https:\/\/doi.org\/10.1093\/ibd\/izab037.","DOI":"10.1093\/ibd\/izab037"},{"key":"2026030517035207501_j_biol-2025-1285_ref_188","doi-asserted-by":"crossref","unstructured":"McInnes, IB, Byers, NL, Higgs, RE, Lee, J, Macias, WL, Na, S, et al.. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther 2019;21:183. https:\/\/doi.org\/10.1186\/s13075-019-1964-1.","DOI":"10.1186\/s13075-019-1964-1"},{"key":"2026030517035207501_j_biol-2025-1285_ref_189","doi-asserted-by":"crossref","unstructured":"Deodhar, A, van der Heijde, D, Sieper, J, Van den Bosch, F, Maksymowych, WP, Kim, T-H, et al.. Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension. Arthritis Rheumatol 2022;74:70\u201380. https:\/\/doi.org\/10.1002\/art.41911.","DOI":"10.1002\/art.41911"},{"key":"2026030517035207501_j_biol-2025-1285_ref_190","doi-asserted-by":"crossref","unstructured":"Yao, Q, Zhu, Y, Ma, Y, Pu, Y, Yang, X, Zhang, Z. Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis. BMC Rheumatol 2025;9:19. https:\/\/doi.org\/10.1186\/s41927-025-00467-1.","DOI":"10.1186\/s41927-025-00467-1"},{"key":"2026030517035207501_j_biol-2025-1285_ref_191","doi-asserted-by":"crossref","unstructured":"Burmester, GR, Stigler, J, Rubbert-Roth, A, Tanaka, Y, Azevedo, VF, Coombs, D, et al.. Safety profile of upadacitinib up to 5\u00a0years in psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis: an integrated analysis of clinical trials. Rheumatol Ther 2024;11:737\u201353. https:\/\/doi.org\/10.1007\/s40744-024-00671-4.","DOI":"10.1007\/s40744-024-00671-4"},{"key":"2026030517035207501_j_biol-2025-1285_ref_192","doi-asserted-by":"crossref","unstructured":"Baraliakos, X, van der Heijde, D, Sieper, J, Inman, RD, Kameda, H, Maksymowych, WP, et al.. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study. Arthritis Res Ther 2024;26:197. https:\/\/doi.org\/10.1186\/s13075-024-03412-8.","DOI":"10.1186\/s13075-024-03412-8"},{"key":"2026030517035207501_j_biol-2025-1285_ref_193","doi-asserted-by":"crossref","unstructured":"Yang, Y, Liu, Y, Li, X, Zeng, Y, He, W, Zhou, J. Uncovering the therapeutic target and molecular mechanism of upadacitinib on sjogren\u2019s syndrome. Biomed Eng Comput Biol 2024;15:11795972241293519. https:\/\/doi.org\/10.1177\/11795972241293519.","DOI":"10.1177\/11795972241293519"},{"key":"2026030517035207501_j_biol-2025-1285_ref_194","doi-asserted-by":"crossref","unstructured":"You, H, Xu, D, Zhao, J, Li, J, Wang, Q, Tian, X, et al.. JAK inhibitors: prospects in connective tissue diseases. Clin Rev Allergy Immunol 2020;59:334\u201351. https:\/\/doi.org\/10.1007\/s12016-020-08786-6.","DOI":"10.1007\/s12016-020-08786-6"},{"key":"2026030517035207501_j_biol-2025-1285_ref_195","doi-asserted-by":"crossref","unstructured":"Michailidou, D, Long, TH, Argenyi, ZB, Noss, EH. Resolution of accelerated nodulosis with upadacitinib in a patient with systemic lupus erythematosus and Jaccoud\u2019s arthropathy. Clin Exp Rheumatol 2023;41(135 Suppl):11\u20132. https:\/\/doi.org\/10.55563\/clinexprheumatol\/hkokxs.","DOI":"10.55563\/clinexprheumatol\/hkokxs"},{"key":"2026030517035207501_j_biol-2025-1285_ref_196","doi-asserted-by":"crossref","unstructured":"Combe, B, Kivitz, A, Tanaka, Y, van der Heijde, D, Simon, JA, Baraf, HSB,\u00a0et al.. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis 2021;80:848\u201358. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219214.","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"2026030517035207501_j_biol-2025-1285_ref_197","doi-asserted-by":"crossref","unstructured":"Westhovens, R, Rigby, WFC, van der Heijde, D, Ching, DWT, Stohl, W, Kay, J, et al.. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis 2021;80:727\u201338. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219213.","DOI":"10.1136\/annrheumdis-2020-219213"},{"key":"2026030517035207501_j_biol-2025-1285_ref_198","doi-asserted-by":"crossref","unstructured":"Prieto-Pe\u00f1a, D, Dasgupta, B. Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. Pol Arch Intern Med 2021;131:171\u201381. https:\/\/doi.org\/10.20452\/pamw.15438.","DOI":"10.20452\/pamw.15438"},{"key":"2026030517035207501_j_biol-2025-1285_ref_199","doi-asserted-by":"crossref","unstructured":"Rigby, W, Buckner, JH, Louis Bridges, S, Nys, M, Gao, S, Polinsky, M, et al.. HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA. Arthritis Res Ther 2021;23:245. https:\/\/doi.org\/10.1186\/s13075-021-02607-7.","DOI":"10.1186\/s13075-021-02607-7"},{"key":"2026030517035207501_j_biol-2025-1285_ref_200","doi-asserted-by":"crossref","unstructured":"Harigai, M, Tsuritani, K, Yoshizawa, Y, Atsumi, T, Tanaka, Y. Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance. Mod Rheumatol 2022;32:508\u201316. https:\/\/doi.org\/10.1093\/mr\/roab050.","DOI":"10.1093\/mr\/roab050"},{"key":"2026030517035207501_j_biol-2025-1285_ref_201","doi-asserted-by":"crossref","unstructured":"Yamada, Z, Muraoka, S, Kawazoe, M, Hirose, W, Kono, H, Yasuda, S, et al.. Long-term effects of abatacept on atherosclerosis and arthritis in older vs. younger patients with rheumatoid arthritis: 3-year results of a prospective, multicenter, observational study. Arthritis Res Ther 2024;26:87. https:\/\/doi.org\/10.1186\/s13075-024-03323-8.","DOI":"10.1186\/s13075-024-03323-8"},{"key":"2026030517035207501_j_biol-2025-1285_ref_202","doi-asserted-by":"crossref","unstructured":"Pombo-Suarez, M, Gomez-Reino, JJ. Abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2019;15:319\u201326. https:\/\/doi.org\/10.1080\/1744666x.2019.1579642.","DOI":"10.1080\/1744666X.2019.1579642"},{"key":"2026030517035207501_j_biol-2025-1285_ref_203","doi-asserted-by":"crossref","unstructured":"Germay, SD, Bagheri, H, Despas, F, Rousseau, V, Montastruc, F. Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study. Rheumatology (Oxford) 2020;59:2360\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kez604.","DOI":"10.1093\/rheumatology\/kez604"},{"key":"2026030517035207501_j_biol-2025-1285_ref_204","doi-asserted-by":"crossref","unstructured":"Tanaka, Y, Matsubara, T, Hashizume, K, Amano, N, Takeuchi, T. Efficacy and safety of abatacept in biologic-na\u00efve patients with active rheumatoid arthritis by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 study. Mod Rheumatol 2022;32:500\u20137. https:\/\/doi.org\/10.1093\/mr\/roab029.","DOI":"10.1093\/mr\/roab029"},{"key":"2026030517035207501_j_biol-2025-1285_ref_205","doi-asserted-by":"crossref","unstructured":"Vicente-Rabaneda, EF, Atienza-Mateo, B, Blanco, R, Cavagna, L, Ancochea, J, Casta\u00f1eda, S, et al.. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review. Autoimmun Rev 2021;20:102830. https:\/\/doi.org\/10.1016\/j.autrev.2021.102830.","DOI":"10.1016\/j.autrev.2021.102830"},{"key":"2026030517035207501_j_biol-2025-1285_ref_206","doi-asserted-by":"crossref","unstructured":"Cope, AP, Jasenecova, M, Vasconcelos, JC, Filer, A, Raza, K, Qureshi, S, et al.. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet 2024;403:838\u201349. https:\/\/doi.org\/10.1016\/s0140-6736(23)02649-1.","DOI":"10.1016\/S0140-6736(23)02649-1"},{"key":"2026030517035207501_j_biol-2025-1285_ref_207","doi-asserted-by":"crossref","unstructured":"Rubbert-Roth, A, Enejosa, J, Pangan, AL, Haraoui, B, Rischmueller, M, Khan, N, et al.. Trial of upadacitinib or abatacept in rheumatoid arthritis. N\u00a0Engl J Med 2020;383:1511\u201321. https:\/\/doi.org\/10.1056\/nejmoa2008250.","DOI":"10.1056\/NEJMoa2008250"},{"key":"2026030517035207501_j_biol-2025-1285_ref_208","doi-asserted-by":"crossref","unstructured":"Molto, A, Arnaud, L, Chartier, M, Panes, A, Lemeille, P, Fautrel, B. Treatment sequences of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a nationwide population-based study in France. Jt Bone Spine 2025;93:106023. https:\/\/doi.org\/10.1016\/j.jbspin.2025.106023.","DOI":"10.1016\/j.jbspin.2025.106023"},{"key":"2026030517035207501_j_biol-2025-1285_ref_209","doi-asserted-by":"crossref","unstructured":"Mohammad Piri, S, Amin Habibi, M, Shool, S, Khazaeli Najafabadi, M, Ahmadpour, S, Alemi, F, et al.. Role of T follicular helper cells in autoimmune rheumatic diseases: a systematic review on immunopathogenesis and response to treatment. Hum Immunol 2024;85:110838. https:\/\/doi.org\/10.1016\/j.humimm.2024.110838.","DOI":"10.1016\/j.humimm.2024.110838"},{"key":"2026030517035207501_j_biol-2025-1285_ref_210","unstructured":"Zuo, Z, Liu, Z, Yuan, K, Wang, Y, Dong, K. Effects and mechanism of the long-snake moxibustion on ankylosing spondylitis based on Th17\/Treg\/Th1 immune imbalance. Zhongguo Zhen Jiu 2018;38:1053\u20137. https:\/\/doi.org\/10.13703\/j.0255-2930.2018.10.006."},{"key":"2026030517035207501_j_biol-2025-1285_ref_211","doi-asserted-by":"crossref","unstructured":"Huang, J, Li, X, Zhu, Q, Wang, M, Xie, Z, Zhao, T. Imbalance of Th17 cells, Treg cells and associated cytokines in patients with systemic lupus erythematosus: a meta-analysis. Front Immunol 2024;15:1425847. https:\/\/doi.org\/10.3389\/fimmu.2024.1425847.","DOI":"10.3389\/fimmu.2024.1425847"},{"key":"2026030517035207501_j_biol-2025-1285_ref_212","doi-asserted-by":"crossref","unstructured":"Zhu, S, Zhou, N, Li, Q, Liu, X. Rewiring immune suppression in NSCLC: roles and plasticity of Tregs and Th17 cells. Front Immunol 2025;16:1658848. https:\/\/doi.org\/10.3389\/fimmu.2025.1658848.","DOI":"10.3389\/fimmu.2025.1658848"},{"key":"2026030517035207501_j_biol-2025-1285_ref_213","doi-asserted-by":"crossref","unstructured":"Habibu, MA, Ahmadpour, S, Tafaroji, J, Eazi, SE, Minaee, P, Mohammadpour, Y, et al.. Two decades rituximab therapy in anti-neutrophil cytoplasmic antibody associated vasculitis. Curr Drug Targets 2025;26.","DOI":"10.2174\/0113894501323529240910015912"}],"container-title":["Open Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/biol-2025-1285\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/biol-2025-1285\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:04:22Z","timestamp":1772730262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/biol-2025-1285\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":213,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,5]]},"published-print":{"date-parts":[[2026,1,23]]}},"alternative-id":["10.1515\/biol-2025-1285"],"URL":"https:\/\/doi.org\/10.1515\/biol-2025-1285","relation":{},"ISSN":["2391-5412"],"issn-type":[{"value":"2391-5412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"20251285"}}